GlassScriptPhysician profile
Francoise J Roux
NPI 1679558449
$38,610.24
in general payments reported to CMS, 2019-2025
42 companies · $3,677 in 2025
The $3,677 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,064 · 2020: $890 · 2021: $1,530 · 2022: $1,709 · 2023: $12K · 2024: $17K · 2025: $3,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $8,699 · Consulting Fee: $1,688 · Travel and Lodging: $1,102 · Education: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,342.00 |
| Food and Beverage | $8,699.10 |
| Consulting Fee | $1,687.50 |
| Travel and Lodging | $1,101.57 |
| Education | $587.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $15,789.59 | 2019-2025 | |
| Harmony Biosciences LLC | $11,520.20 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $3,454.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,868.91 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Avadel Cns Pharmaceuticals, LLC | $888.68 | 2023-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.02 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $405.20 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $371.08 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $361.81 | 2020-2025 | Glassia, Hyqvia |
| Mallinckrodt Hospital Products INC. | $336.98 | 2020-2023 | Acthar |
| Axsome Therapeutics, INC. | $255.44 | 2022-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $240.90 | 2021-2025 | Dupixent |
| Genzyme Corporation | $207.39 | 2019-2025 | |
| Verona Pharma, INC. | $202.98 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $176.85 | 2025 | Yupelri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $176.61 | 2019-2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $169.62 | 2019-2020 | |
| Amgen INC. | $168.77 | 2022-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $143.61 | 2019-2022 | |
| Covis Pharma Gmbh | $141.94 | 2021-2022 | |
| Baxter Healthcare | $115.95 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Advanced Respiratory, INC | $102.85 | 2019-2020 | |
| Lilly USA, LLC | $99.55 | 2025 | Zepbound, Mounjaro |
| Philips North America LLC | $92.30 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Insmed, INC. | $88.92 | 2019-2024 | Arikayce |
| 3b Medical, INC. | $78.26 | 2025 | Luna |
| Novartis Pharmaceuticals Corporation | $68.61 | 2019 | |
| Mallinckrodt Enterprises LLC | $66.03 | 2019 | |
| Watermark Medical, INC. | $65.50 | 2024 | |
| Electromed, INC. | $42.78 | 2023-2025 | Smartvest |
| Zoll Respicardia, INC. | $37.98 | 2024 | Remede System |
| Abbvie INC. | $37.07 | 2025 | |
| Alk-Abello, INC | $33.10 | 2024 | Grastek, Ragwitek, Odactra |
| Grifols USA, LLC | $23.96 | 2019 | |
| Allergan, INC. | $23.90 | 2019 | |
| Phadia US INC. | $23.03 | 2019 | |
| Azurity Pharmaceuticals, INC. | $22.60 | 2025 | Alvesco |
| Itamar Medical INC | $22.53 | 2025 | Watchpatone |
| Inspire Medical Systems, INC. | $22.26 | 2025 | Inspire |
| Inogen, INC. | $16.86 | 2024 | |
| Merck Sharp & Dohme LLC | $16.00 | 2020 | |
| Circassia INC. | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francoise Roux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.